SEC filings and other documents

Q1 2026 saw revenue and net income growth, led by FIRDAPSE and AGAMREE sales.

Strong growth in rare disease portfolio, robust cash, and strategic expansion plans for 2026.

Rare disease focus, strong growth, and $700M cash drive expansion and patient-first innovation.

Record 2025 revenues and high growth in rare disease therapies fuel ongoing expansion.

2025 revenues rose 19.8% to $589M, with double-digit growth forecast for 2026.

Rare disease growth strategy centers on Agamree, Firdapse, and targeted business development.

Expanding rare disease portfolio with strong growth in Firdapse and Agamree, backed by solid cash reserves.

Rare disease portfolio drives double-digit growth, strong cash, and strategic expansion plans.

Q3 2025 revenue up 15.3% YoY; guidance raised amid strong rare disease therapy demand.

FIRDAPSE and AGAMREE drive growth through innovation, partnerships, and targeted market expansion.

FIRDAPSE and AGAMREE drive growth through strategic focus, market access, and ongoing innovation.

Sustained growth in rare disease assets, with FIRDAPSE and AGAMREE as key value drivers.

Firdapse and GammaRay drive growth through focused commercialization, diagnostics, and lifecycle management.

Record Q2 revenue and strong product growth support a positive outlook for 2025.

Record sales, robust growth, and strategic expansion position the company for future acquisitions.

Record revenue growth and expanding rare disease therapies position for continued success.

Q1 revenues surged 43.6% year-over-year, supporting raised full-year guidance and strong cash growth.

Strong orphan drug growth, major LEMS and DMD opportunities, and active business development focus.

2024 saw record revenue and profit growth, with robust outlook and strong cash for 2025.